Cathy Burgess will speak at the conference hosted by the Food and Drug Institute (FDLI). Her session is titled “Medical Products in a Post-COVID and EUA World.”
With signs that the pandemic may be waning, what does this mean for FDA and industry as we transition to a post-pandemic world? The panel will address what COVID-related work we expect FDA to continue and whether resources might be diverted back to other initiatives, whether some flexibilities that were provided during COVID may become permanent, and what learnings can be leveraged for the future. Speakers will also discuss the post-emergency declaration scenario, including what will happen with EUAs, what FDA has said thus far regarding EUA transitions, and why there is still a PHE for Zika and whether companies should be thinking about COVID in the same way.
Cathy also serves on the FDLI board of directors.
For more information, click here.